5.2 Antimetabolites & Folate Antagonists

5.2 Antimetabolites & Folate Antagonists

Antimetabolites represent one of the oldest and most versatile classes of antineoplastic agents. By mimicking physiological purines, pyrimidines, and folate cofactors, these agents disrupt nucleic acid biosynthesis, halt replication forks, and trigger programed cell death. Because their cytotoxicity is exquisitely dependent on active DNA replication, antimetabolites are S-phase specific cell-cycle antineoplastics. Consequently, their therapeutic efficacy and toxicity profiles are highly sensitive to schedule and duration of exposure rather than peak concentrations alone.

---

1. Folate Antagonists: Methotrexate & Pemetrexed

Folate antagonists interfere with intracellular one-carbon transfer reactions essential for de novo synthesis of purine nucleotides (adenine and guanine) and thymidylate ($dTMP$).

+-----------------------------------------------------------------------------+
|                 FOLATE METABOLIC PATHWAY & ANTIFOLATE TARGETS               |
|                                                                             |
|   Dietary Folate / Dihydrofolate (DHF)                                      |
|                    |                                                        |
|                    | <--- METHOTREXATE (Potent Competitive Inhibitor)       |
|                    v      PEMETREXED (Secondary Target)                     |
|         [Dihydrofolate Reductase (DHFR)]                                    |
|                    |                                                        |
|                    v                                                        |
|          Tetrahydrofolate (THF) <========== [LEUCOVORIN / FOLINIC ACID]     |
|                    |                         (Bypasses DHFR Inhibition)     |
|                    v                                                        |
|          5,10-Methylene-THF                                                 |
|                    |                                                        |
|                    +------------------------+                               |
|                    |                        |                               |
|   <--- PEMETREXED  |                        | <--- 5-FU (FdUMP + THF Ternary|
|        (Primary)   v                        v      Complex Inhibits TS)     |
|          [Thymidylate Synthase]       [GAR / AICAR Transformylases]         |
|                    |                        |                               |
|                    v                        v                               |
|             dTMP (Thymidine)              Purines (Adenine, Guanine)        |
|                    |                        |                               |
|                    +----------->+<----------+                               |
|                                 |                                           |
|                                 v                                           |
|                     [DNA / RNA Biosynthesis]                                |
+-----------------------------------------------------------------------------+

A. Methotrexate (MTX) & High-Dose MTX (HDMTX) Protocols

• Mechanism: Polyglutamated intracellularly; competitively inhibits Dihydrofolate Reductase (DHFR) ($K_i < 1\text{ pM}$), depleting intracellular $N^5,N^{10}$-methylene-THF and halting both thymidylate and de novo purine synthesis.
• HDMTX Definitions: Doses $\ge 500\text{ mg/m}^2$ up to $12,000\text{ mg/m}^2$ (used in Osteosarcoma, Primary CNS Lymphoma, ALL, High-Grade B-cell Lymphomas). HDMTX passive diffusion overcomes cellular transport resistance but requires strict rescue to prevent fatal host toxicity.

Mandatory HDMTX Supportive Care Requirements:

1. Urine Alkalinization & Hydration:
   • Mechanism: Methotrexate and its primary hepatic metabolite 7-hydroxy-methotrexate (7-OH-MTX) have very poor water solubility in acidic environments (isoelectric point pH ~4.8–5.5). In acidic tubular urine, they precipitate into insoluble crystals, causing intratubular obstruction, direct tubular necrosis, and acute renal failure.
   • Goal: Pre-hydrate with IV fluids containing Sodium Bicarbonate ($40\text{--}50\text{ mEq/L}$) at $150\text{--}200\text{ mL/hr}$ to ensure urine pH $\ge 7.0$ and urine output $\ge 100\text{ mL/hr}$ prior to starting MTX and maintained continuously until serum MTX $< 0.05\text{--}0.1;\mu\text{mol/L}$.
2. Third-Space Fluid Drainage:
   • Methotrexate slowly distributes into pathological third-space collections (pleural effusions, ascites). As systemic MTX levels fall, the drug slowly diffuses back into the intravascular compartment, creating a persistent, low-concentration plateau that bypasses renal clearance and causes lethal myelosuppression and mucositis. All significant pleural effusions and ascites must be drained prior to HDMTX.
3. Drug-Drug Interactions (Contraindicated / Hold):
   • NSAIDs & Salicylates: Inhibit renal prostaglandin-mediated perfusion and compete for organic anion transporters (OAT1/OAT3), reducing MTX clearance by up to 50%.
   • Proton Pump Inhibitors (PPIs - Omeprazole, Esomeprazole): Inhibit the BCRP (breast cancer resistance protein) and OAT transporter-mediated renal elimination of MTX. Switch to H2RAs (famotidine) or hold PPIs 48–72 hours prior.
   • Penicillins, Cephalosporins, Probenecid: Compete directly for OAT3 tubular secretion.
   • Trimethoprim-Sulfamethoxazole (Bactrim): Additive DHFR inhibition + protein displacement; hold on HDMTX days.
4. Leucovorin (Folinic Acid / 5-formyl-THF) Rescue:
   • Leucovorin is a reduced folate cofactor that does not require DHFR for activation. It directly replenishes the intracellular reduced folate pool, rescuing normal dividing host tissues (bone marrow, gastrointestinal mucosa) from MTX toxicity.
   • Timing: Typically initiated 24 hours following the start of MTX infusion (starting too early abrogates antineoplastic efficacy; starting $>40\text{--}48\text{ hours}$ late leads to irreversible mucosal and marrow destruction).
   • Dosing is dynamically adjusted using institutional MTX Elimination Nomograms (e.g., standard dose: $15\text{ mg PO/IV q6h}$; escalated to $50\text{--}150\text{ mg/m}^2\text{ IV q3h}$ if 24h, 48h, or 72h levels exceed safety thresholds).

+-----------------------------------------------------------------------------+
|                  HDMTX LEUCOVORIN RESCUE NOMOGRAM ALGORITHM                 |
|                                                                             |
|   TIME POST-START   NORMAL EXPECTED MTX LEVEL   ACTION / LEUCOVORIN DOSE    |
|   -----------------------------------------------------------------------   |
|   24 Hours          < 5 - 10 umol/L             Standard Rescue: 15 mg q6h  |
|   48 Hours          < 1.0 umol/L                Continue 15 mg q6h          |
|   72 Hours          < 0.1 - 0.2 umol/L          Continue until <0.05-0.1 uM |
|                                                                             |
|   IF DELAYED ELIMINATION OCCURS:                                            |
|   48h MTX >= 5 umol/L OR 72h MTX >= 1 umol/L:                               |
|   -> Increase Leucovorin to 100-150 mg/m2 IV q3-6h                          |
|   -> Intensify hydration + NaHCO3 (maintain urine pH >= 7.5)                |
|   -> If Renal Failure + MTX > 1-2 umol/L: Administer GLUCARPIDASE           |
+-----------------------------------------------------------------------------+

1. Glucarpidase (Voraxaze - Recombinant Carboxypeptidase G2):
   • Indication: Indicated for the treatment of toxic plasma methotrexate concentrations ($>1;\mu\text{mol/L}$) in patients with delayed MTX clearance due to acute impaired renal function.
   • Mechanism: Bacterial enzyme that rapidly hydrolyzes extracellular methotrexate into inactive metabolites: 4-deoxy-4-amino-$N^{10}$-methylpteroic acid (DAMPA) and glutamate, providing an alternate non-renal clearance route.
   • Dosing: $50\text{ Units/kg}$ as a single IV injection over 5 minutes.
   • Critical Interaction Rule: Do NOT administer Leucovorin within 2 hours before or after Glucarpidase. Glucarpidase hydrolyzes leucovorin as well, rendering both ineffective. Continue leucovorin $\ge 2\text{ hours}$ after glucarpidase.
   • Laboratory Measurement Pearl: DAMPA cross-reacts with standard clinical immunoassays (CEDIA/FPIA) for MTX, producing falsely elevated MTX readings for 48 hours post-glucarpidase. Only chromatographic methods (LC-MS/MS) accurately measure MTX post-glucarpidase. Continue leucovorin based on pre-glucarpidase levels or institutional nomograms for 48 hours.

B. Pemetrexed (Alimta): Multi-Targeted Antifolate

• Mechanism: Inhibits Thymidylate Synthase (TS), DHFR, and glycinamide ribonucleotide formyltransferase (GARFT). Indicated for non-squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma.
• Mandatory Premedications & Safety Rules:
  1. Folic Acid: $400\text{--}1,000;\mu\text{g PO daily}$ starting $\ge 7\text{ days}$ prior to cycle 1, continuing daily throughout therapy, and for 21 days after the last dose. Prevents life-threatening myelosuppression and severe mucositis/diarrhea.
  2. Vitamin B12: $1,000;\mu\text{g IM}$ starting 1 week prior to cycle 1 and repeated every 9 weeks (every 3 cycles).
  3. Dexamethasone: $4\text{ mg PO BID}$ on days $-1, 0, +1$ (day before, day of, day after pemetrexed) to prevent severe cutaneous erythematous rash.
  4. Renal Cutoff & NSAID Interactions: Contraindicated if $\text{CrCl} < 45\text{ mL/min}$. Hold short half-life NSAIDs (ibuprofen, ketorolac) 2 days before and 2 days after ($5\text{ days}$ for long half-life NSAIDs like piroxicam/nabumetone) in patients with mild-to-moderate renal impairment ($ ext{CrCl } 45\text{--}79\text{ mL/min}$).

---

2. Pyrimidine Analogs: Fluoropyrimidines & Cytarabine

+-----------------------------------------------------------------------------+
|               FLUOROPYRIMIDINE BIOACTIVATION & DPYD PATHWAY                 |
|                                                                             |
|            Oral CAPECITABINE (Prodrug)                                      |
|                 |                                                           |
|                 | (Hepatic Carboxylesterase - CES1/CES2)                    |
|                 v                                                           |
|            5'-Deoxy-5-fluorocytidine (5'-DFCR)                              |
|                 |                                                           |
|                 | (Cytidine Deaminase - CDA in Liver/Tumor)                 |
|                 v                                                           |
|            5'-Deoxy-5-fluorouridine (5'-DFUR)                               |
|                 |                                                           |
|                 | (Thymidine Phosphorylase - TP, High in Tumors)            |
|                 v                                                           |
|   +---------------------------------------+                                 |
|   |         5-FLUOROURACIL (5-FU)         |                                 |
|   +---------------------------------------+                                 |
|        |                              |                                     |
|        | Catabolism (>80%)            | Anabolic Bioactivation (<20%)       |
|        v                              v                                     |
|   [DPYD / DPD Enzyme]             +-------------------+                     |
|   (Inactivated to DHFU)           | Active Metabolites|                     |
|                                   +-------------------+                     |
|   *DEFICIENCY (*2A, *13, c.2846):           |                               |
|   Profound 5-FU Accumulation                +---> FdUMP (Inhibits TS)       |
|   -> Fatal Neutropenic Sepsis,              +---> FUTP (Incorporates RNA)   |
|      Diarrhea, Toxic Megacolon              +---> FdUTP (Incorporates DNA)  |
+-----------------------------------------------------------------------------+

A. 5-Fluorouracil (5-FU) & Capecitabine

• Mechanism: Converted to fluorodeoxyuridine monophosphate (FdUMP), which forms a stable ternary covalent complex with Thymidylate Synthase (TS) and 5,10-methylene-THF, inhibiting thymidine synthesis. Also converted to FUTP (incorporated into RNA, inhibiting processing) and FdUTP (incorporated into DNA).
• Bolus vs. Continuous Infusion 5-FU Toxicity Profile:
  • IV Bolus 5-FU: Primarily RNA incorporation $\rightarrow$ Dose-Limiting Toxicity (DLT): Myelosuppression (neutropenia, thrombocytopenia) and Mucositis.
  • Continuous IV Infusion 5-FU (e.g., 46-hr infusion in FOLFOX/FOLFIRI): Prolonged TS inhibition $\rightarrow$ DLT: Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia [PPE]), Diarrhea, and Coronary Vasospasm / Cardiotoxicity (angina, ischemic ECG changes).
• Leucovorin Modulation with 5-FU:
  • Critical Difference from MTX: In 5-FU regimens, Leucovorin is NOT a rescue agent; it is a biochemical enhancer. Leucovorin supplies excess 5,10-methylene-THF, which stabilizes the ternary inhibitory complex with TS, dramatically increasing 5-FU cytotoxicity and host toxicity.
• Capecitabine (Xeloda): Oral prodrug converted to 5-FU inside tumor cells via a 3-step enzymatic cascade culminating in Thymidine Phosphorylase (TP).
  • Dosed with food (within 30 minutes after a meal).
  • Drug-Drug Interactions: Severe inhibition of CYP2C9 $\rightarrow$ massive increase in Warfarin levels/INR with fatal bleeding risk. Switch warfarin to LMWH or DOACs. Aluminum/magnesium antacids increase capecitabine absorption/AUC.

B. DPYD (Dihydropyrimidine Dehydrogenase) Pharmacogenomics

• Biology: DPD is the rate-limiting enzyme responsible for $>80%$ of 5-FU catabolism in the liver.
• Genetic Variants: DPYD *2A (c.1905+1G>A), *13 (c.1679T>G), c.2846A>T, and HapB3 (c.1129-5923C>G / c.1236G>A).
• Clinical Phenotypes (CPIC Guidelines):
  • Normal Metabolizer (Activity Score 2.0): Standard 100% dosing.
  • Intermediate Metabolizer (Activity Score 1.0–1.5): 50% starting dose reduction, titrate in subsequent cycles based on clinical tolerance.
  • Poor Metabolizer (Activity Score 0–0.5): Complete DPD deficiency. Strongly avoid fluoropyrimidines (5-FU, capecitabine, trifluridine/tipiracil) due to extreme risk of fatal toxic megacolon, pancytopenia, and neurotoxicity.

C. Uridine Triacetate (Vistogard): Fluoropyrimidine Antidote

• Indication: FDA-approved specific antidote for 5-FU or capecitabine overdose (regardless of symptoms) or for patients exhibiting early-onset, life-threatening toxicities (severe diarrhea, mucositis, cardiotoxicity, neutropenia) within 96 hours of administration.
• Mechanism: Oral prodrug of uridine. Phosphorylated to UTP, which competitively displaces toxic fluorouridine metabolites from RNA incorporation, terminating cellular toxicity.
• Dosing: 10 grams orally every 6 hours for 20 doses (children: $6.2\text{ g/m}^2\text{ PO q6h}$). Must be initiated within 96 hours of 5-FU/capecitabine completion for maximal survival benefit ($>95%$ survival vs. $<15%$ in historical controls).

D. Cytarabine (Ara-C): Low-Dose vs. High-Dose (HiDAC)

• Mechanism: Deoxycytidine analog; phosphorylated to Ara-CTP, which inhibits DNA polymerase-$\alpha$ and $-\beta$ and incorporates into DNA causing chain termination.
• High-Dose Cytarabine (HiDAC $\ge 1,000\text{--}3,000\text{ mg/m}^2$ in AML):
  1. Cerebellar Neurotoxicity: Manifests as dysmetria, past-pointing, ataxia, dysarthria, nystagmus, and confusion. Caused by Purkinje cell degeneration. Risk factors: Age $>60\text{ years}$, renal dysfunction ($\text{Serum Cr } \ge 1.5\text{--}2.0\text{ mg/dL}$). Mandatory neurological assessments (finger-to-nose, signature/handwriting, gait) prior to EVERY dose. Discontinue HiDAC immediately if ataxia or dysmetria develops (neurotoxicity is irreversible if dosing continues).
  2. Chemical / Hemorrhagic Conjunctivitis: Cytarabine is secreted in high concentrations in tears, causing severe corneal epithelial irritation, photophobia, pain, and blindness. Mandatory Prophylaxis: Corticosteroid ophthalmic drops (Prednisolone acetate 1% or Dexamethasone 0.1% 1–2 drops in both eyes QID) starting 6–12 hours prior to first HiDAC dose and continuing for 48–72 hours after completion.

---

3. Purine Analogs & Thiopurines (6-MP, 6-TG, Fludarabine, Cladribine)

+-----------------------------------------------------------------------------+
|                 6-MERCAPTOPURINE (6-MP) METABOLIC REGULATION                |
|                                                                             |
|                           6-MERCAPTOPURINE (6-MP)                           |
|                                      |                                      |
|         +----------------------------+----------------------------+         |
|         |                            |                            |         |
|         v                            v                            v         |
|  [Xanthine Oxidase]          [TPMT / NUDT15]              [HPRT Pathway]    |
|  (Metabolizes to             (S-methylation to            (Bioactivates to  |
|   inactive 6-thiouric acid)   inactive 6-MeMP)             active 6-TGN)    |
|         |                            |                            |         |
|         x (BLOCKED BY                *DEFICIENCY (*2, *3):        v         |
|            ALLOPURINOL/              Shunts drug to 6-TGN  -> Cytotoxicity  |
|            FEBUXOSTAT)               -> Severe Marrow         (Marrow       |
|         |                               Failure                Suppression) |
|         v                                                                   |
|   MASSIVE SHUNT TO 6-TGN                                                    |
|   -> FATAL MYELOSUPPRESSION                                                 |
|   *MANDATORY 67-75% DOSE REDUCTION OF 6-MP WITH ALLOPURINOL*                |
+-----------------------------------------------------------------------------+

A. Thiopurine Drug Interactions & Pharmacogenomics

• 6-MP and Xanthine Oxidase (XO) Inhibitors: Allopurinol and febuxostat block XO-mediated catabolism of 6-MP. When co-prescribed for tumor lysis syndrome or hyperuricemia, the dose of oral 6-MP MUST be reduced by 67% to 75% (administer only 25–33% of standard dose). Note: 6-Thioguanine (6-TG) is deaminated by guanase, not XO, and does not require dose reduction with allopurinol.
• TPMT and NUDT15 Pharmacogenomics: Thiopurine S-methyltransferase (TPMT) and NUDT15 inactivate thiopurines. Patients homozygous for deficient alleles (poor metabolizers) accumulate massive levels of active 6-thioguanine nucleotides (6-TGN), causing fatal bone marrow aplasia. CPIC guidelines require 80–90% dose reductions and reduced dosing frequency in homozygous poor metabolizers.

B. Purine Analogs & Profound Immunosuppression (Fludarabine, Cladribine)

• Mechanism: Inhibit ribonucleotide reductase and DNA polymerase, inducing apoptosis in resting and dividing lymphocytes.
• Lymphodepletion & CD4+ T-cell Suppression: Produces profound, long-lasting CD4+ and CD8+ lymphopenia persisting for 1 to 2 years.
• Supportive Mandates:
  • PJP Prophylaxis: Bactrim (or dapsone/atovaquone) until CD4+ $\ge 200\text{ cells/}\mu\text{L}$.
  • Antiviral Prophylaxis: Acyclovir or valacyclovir for HSV/VZV reactivation.
  • Irradiated Blood Products: Transfusion of non-irradiated cellular blood products carries a high risk of fatal Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD) due to donor lymphocyte engraftment in the immunosuppressed host. All blood products must be irradiated for life following purine analog therapy.